Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • PepGen Inc. led the biotech surge with around 121% stock increase, driven by promising gene therapy clinical trials and supportive analyst upgrades.
  • HeartSciences Inc. rallied 50%, boosting market confidence through advancements in cardiovascular diagnostic technologies and expanding market focus.
  • Jasper Therapeutics rose ~11.5%, reflecting positive market response to its strategic pivot towards chronic hives research and operational restructuring.

Biotech stocks made headlines on Thursday, September 25, 2025, with standout performances driven by unique company developments and promising clinical progress. Despite a challenging market environment, PepGen Inc., HeartSciences Inc., and Jasper Therapeutics delivered remarkable gains, fueled by innovation, strategic pivots, and investor optimism. These surges highlight how focused research and operational strategies continue to shape valuation dynamics within the biotech sector.

PepGen Inc. (NASDAQ:PEPG)

PepGen Inc., a clinical-stage biotechnology company headquartered in Boston, specializes in developing oligonucleotide therapies aimed at severe neuromuscular and neurological diseases. The company’s flagship candidates include PGN-EDO51 for Duchenne muscular dystrophy and PGN-EDODM1 for myotonic dystrophy type 1, both in Phase 2 trials. On September 25, PepGen’s stock soared 121.05% to USD 5.88 following positive trial results and a $100 million public offering to fund ongoing research.

HeartSciences Inc. (NASDAQ:HSCS)

HeartSciences Inc. focuses on innovative cardiovascular diagnostic technologies, seeking to transform cardiac care through portable and early detection devices. Its core products cater to decentralized healthcare and telemedicine initiatives. The company’s stock rallied 50%, closing at USD 0.15, as market responded positively to advancements in its technology programs and strategic partnerships aimed at expanding market reach. The surge reflects growing market confidence in HeartSciences’ potential to disrupt cardiac diagnostics.

Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Jasper Therapeutics, a biopharmaceutical company committed to developing therapies for autoimmune and inflammatory diseases, announced a strategic realignment towards chronic hives research alongside restructuring efforts to optimize operations. This pivot was well received by the market, driving a 11.48% gain to USD 0.10. Jasper’s renewed focus is intended to strengthen its product pipeline and capitalize on unmet medical needs in dermatology, signaling potential for sustained future growth.